NRG1 and neoplasm: Additionally, ERBB3-targeting antibodies are now entering clinical trial for other indications (e.g. seribantumab for NRG1-fusion harboring tumours) [42] (NCT04383210), which may provide further options for clinical investigation of this treatment concept.